1 We studied the pharmacological properties of native rat brain and heterologously expressed rat a4b2 nicotinic receptors immunoprecipitated onto a ®xed substrate with the anti-a4 antibody mAb 299. 2 Immunodepletion with the anti-b2 antibody mAb 270 showed that 89% of the mAb-299-precipitated rat brain receptors contained b2. 
Introduction
Several lines of evidence suggest that the predominant mammalian brain nicotinic subtype contains a4 and b2 subunits. First, the a4 and b2 mRNAs are the most abundant and widespread nicotinic subunit mRNAs in the rat brain (Zoli et al., 1995) . Second, the a4 subunit forms functional nicotinic receptors with the b2 subunit in heterologous expression systems (reviewed in Sargent, 1993) . Third, the a4 and b2 subunits co-assemble into a brain nicotinic receptor (Whiting & Lindstrom, 1987) that accounts for most of the high-anity rat brain [ 3 H]-cytisine binding (Flores et al., 1991) . Fourth, immunohistochemical localization con®rms the widespread distribution of the b2 protein in the rat brain (Hill et al., 1993) and immunodepletion with the anti-b2 antibody mAb 270 removes 92% of the [ Mouse brain synaptosomes also appear to contain two major classes of nicotinic receptors that mediate a-bungarotoxin insensitive ACh-induced 86 Rb + eux (Marks et al., 1999) . The EC 50 s of these two receptor classes for ACh-induced 86 
Rb
+ eux are 7.2+0.3 mM ACh (mean+standard error of the mean s.e.m.) and 550+60 mM ACh (Marks et al., 1999) . The nicotinic antagonist dihydro-b-erythroidine (DHbE) inhibits 86 Rb + eux through the more ACh-sensitive receptors *ten times more potently (IC 50 of 0.2 mM DHbE) than it inhibits 86 Rb + eux through the less ACh-sensitive receptors (IC 50 of 3 mM DHbE) (Marks et al., 1999) . Both receptor types are distributed throughout the brain and contain b2 nicotinic subunits (Marks et al., 1999) . A regional correlation between high-anity nicotine binding and DHbE-sensitive 86 
+ eux in the brain suggests that the DHbE-sensitive receptors are a4b2 nicotinic receptors (Marks et al., 1999) . However, the identity of the DHbE-insensitive receptors is unclear.
+[ 3 H]-Epibatidine binding to immunoprecipitated receptors allows us to compare the pharmacological properties of isolated native brain nicotinic receptors containing a known subunit with those of heterologously expressed nicotinic receptor subtypes, under identical experimental conditions and without confounding intracellular factors. To determine whether a4-containing rat brain nicotinic receptors and heterologously expressed rat a4b2 nicotinic receptors exhibit both high-and low-anity +[
3 H]-epibatidine binding, we immunoprecipitated solubilized nicotinic receptors with the anti-a4 antibody mAb 299 (Whiting & Lindstrom, 1988) and measured their +[
3 H]-epibatidine concentration-binding reactions. The results show that both receptor types display highand low-anity +[
3 H]-epibatidine binding. To determine whether the antagonist pro®le of the high-anity native receptors matched that of the high-anity heterologously expressed receptors, we measured the ability of two competitive antagonists (DHbE, N-n-decylnicotinium iodide (NDNI)) to inhibit 30 pM +[
3 H]-epibatidine binding to these receptors. Previous studies show that DHbE inhibits highanity +[ 3 H]-epibatidine binding to rat forebrain homogenates (Houghtling et al., 1995) . NDNI is a novel nicotine analogue. The results show that the high-anity native brain and heterologously expressed a4b2 receptors exhibit similar K i s for DHbE and NDNI.
Methods

Solubilization of rat brain receptors
Adult rats were killed by an overdose of pentobarbital sodium or CO 2 inhalation according to the guidelines of the University of California Animal Use Committee. After killing the rats, the entire brain was removed and frozen immediately in liquid nitrogen. Homogenates were prepared from the frozen brains using a previous protocol (Gerzanich et al., 1995) . The brain homogenates were stored at 7808C in a lysis buer containing (mM): NaCl 50, Na phosphate buer 50, EGTA 5, EDTA 5, 2% Triton X-100, and Complete 2 protease inhibitor (1 tablet per 40 ml of lysis buer, Boehringer Mannheim, Indianapolis, IN, U.S.A.). We used a CuSO 4 assay (Micro BCA Protein Assay, Pierce, Rockford, IL, U.S.A.) to measure the homogenate total protein concentration.
Oocyte expression
Stage V ± VI oocytes were surgically isolated from anaesthetized Xenopus using a previous protocol (Quick & Lester, 1994) in accordance with the guidelines of the University of California Animal Use Committee. Capped rat a4-1 and b2 cRNAs were synthesized in vitro from linearized pBluescript plasmids using the mMessage mMachine RNA transcription kit (Ambion, Austin, TX, U.S.A.). The most probable subunit stoichiometry for a4b2 receptors expressed in Xenopus oocytes is (a4) 2 (b2) 3 (Cooper et al., 1991) . Therefore, we injected the a4 and b2 cRNAs in a 2 : 3 (weight/weight) stoichiometric ratio. Each oocyte received 15 ng of a4-1 RNA and 22.5 ng of b2 RNA. The injected oocytes were incubated for 2 ± 3 days in a modi®ed Barth's solution (mM): NaCl 96, HEPES 5, Napyruvate 2.5, KCl 2, CaCl 2 1.8, MgCl 2 1, 2.5 mg ml 71 gentamycin, 5% horse serum, pH 7.4 at 188C. The oocytes were then solubilized as previously described (Peng et al., 1994; Gerzanich et al., 1995) using the same buer that we used for the rat brain receptors (see above).
Adenoviral expression in CV-1 cells
Recombinant adenoviruses encoding the rat nicotinic a4 subunit (Adteta4), the rat nicotinic b2 subunit (Adtetb2), and the tetracycline-dependent trans-activator (AdtTA) were prepared as described previously (Neering et al., 1996; Hardy et al., 1997 ) using a tetracycline-regulated promoter (Gossen & Bujard, 1992) , rather than a simple CMV one. Recombinant adenoviruses were puri®ed from infected HEK cells using a CsCl gradient (Jones & Shenk, 1979) . The virus titer was determined from the OD 260 (1 OD unit=5610 10 plaqueforming units (p.f.u.) in HeLa cells). Ten p.f.u. of each virus (Adteta4, Adtetb2, AdtTA) were added per cell to a just con¯uent CV-1 monolayer to express the a4b2 receptors. After a 24 h incubation, the cells were washed with PBS, frozen at 7808C, and then thawed in the lysis buer (above). After thawing and lysis, the homogenate was centrifuged at 13,000 r.p.m. The supernatant was removed and frozen at 7808C.
Vaccinia viral expression in CV-1 cells
The rat a4 and b2 subunits cDNAs were excised from pBluescript and subcloned into the vaccinia expression vector pTM1 (Elroy-Stein et al., 1989) to obtain the cDNA plasmids pTM1a4 and pTM1b2. Expression in pTM1 is under the control of a T7 RNA polymerase promoter, aided by capindependent translation conferred by the encephalomyocarditis virus 5' untranslated leader sequence (Elroy-Stein et al., 1989) . CV-1 cells, grown to 60 ± 70% con¯uence in 83 cm 2 asks in a 5% CO 2 incubator, were infected with the recombinant vaccinia virus VTF7-3 (Fuerst et al., 1986) . The cells were infected at a multiplicity of infection of ®ve viral particles per cell for 30 min at 378C in serum-free MEM medium supplemented with non-essential amino acids and sodium pyruvate. VTF7-3 is a recombinant virus that continuously expresses T7 RNA polymerase in infected cells. After infection, CV-1 cells were washed three times in MEM medium and each¯ask was transfected with 4 mg of pTM1a4, 4 mg of pTM1b2, and 24 ml lipofectin in serum-free MEM medium. The DNA-lipofectin mixture was allowed to adsorb to the cells for 16 h at 378C. After this incubation, the CV-1 cells were washed three times and allowed to recover in MEM medium supplemented with 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, streptomycin (100 mg ml 71 ), and penicillin (100 units ml 71 ). After recovery, the infectedtransfected cells were frozen at 7808C prior to solubilization in the same buer used for the oocyte and rat brain experiments. (Peng et al., 1994; Gerzanich et al., 1995) ) by adding 0.5 or 2 mg of mAb 299 in 100 ml of 10 mM Na bicarbonate (pH 8.8) for an overnight incubation at 48C. We blocked the coated wells with 3% bovine serum albumin in 200 ml of PBS-Tween buer (100 mM NaCl, 10 mM Na phosphate, 0.05% Tween 20, pH 7.5) for 2 h at 48C and rinsed the blocked wells three times with PBS-Tween buer. Aliquot parts (100 ml) of the solubilized receptors in lysis buer were added to the wells and incubated overnight at 48C. We rinsed the wells three times with PBS-Tween the following day and added the appropriate +[
Measurement of +[
3 H]-epibatidine concentration in PBS-Tween to each well for 4 h at 20 ± 238C (Houghtling et al., 1995) . To avoid ligand depletion at low +[
3 H]-epibatidine concentrations (0.001 ± 0.3 nM), we incubated each well in 2 ± 4 ml of the +[ 3 H]-epibatidine solution (Houghtling et al., 1995) . At higher +[
3 H]-epibatidine concentrations (51 nM), we used an incubation volume of 200 ml. The amount of receptor added to the wells was adjusted so that the depletion of free +[
3 H]-epibatidine was 510%. The free ligand concentrations in the +[
3 H]-epibatidine concentration-binding experiments were corrected for ligand depletion. After the +[
3 H]-epibatidine incubation, the wells were rinsed three times with ice-cold PBS-Tween buer, placed whole into 1 ml of scintillation¯uid, and counted. We measured nonspeci®c +[ 3 H]-epibatidine binding three dierent ways. The ®rst method was to measure +[
3 H]-epibatidine binding as described above but in the presence of 100 mM cold (7) nicotine (Houghtling et al., 1995) . The second method (used only with the recombinant receptors) was to measure +[
3 H]-epibatidine binding to the immunoprecipitated protein from un-injected oocytes or uninfected CV-1 cells. The third method was to measure +[
3 H]-epibatidine binding to uncoated, but blocked, wells (Peng et al., 1994) . The nonspeci®c binding measured by these three methods was not signi®cantly dierent. Thus, +[
3 H]-epibatidine binding to the uncoated, blocked wells and background radiation were the main sources of nonspeci®c binding. The +[ 
Kinetic measurements
The forward rate constant for +[ 3 H]-epibatidine binding to the a4b2 receptors expressed in oocytes at 20 ± 238C was measured by placing wells containing the immunoprecipitated receptors in 4 ml of 0.03 nM +[
3 H]-epibatidine for times ranging from 1 ± 300 min. The forward binding reaction was stopped by adding an excess (1 mM) of cold (7)-nicotine. After stopping the reaction, we rinsed the wells three times with ice-cold PBS-Tween and counted the bound +[
3 H]-epibatidine. The backward rate constant for +[
3 H]-epibatidine binding to the a4b2 receptors at 20 ± 238C was measured by incubating wells containing the immunoprecipitated receptors in 4 ml of 0.03 mM +[
3 H]-epibatidine for 4 h. After the 4 h incubation, we stopped the reaction by adding 1 mM cold (7)-nicotine to the wells. At times ranging from 1 ± 600 min after adding the nicotine, the wells were rinsed three times with icecold PBS-Tween and counted. Nonspeci®c binding was measured by adding 1 mM cold (7) 
This approximation assumes that 0.03 nM was 44 the K D for the high-anity +[ 3 H]-epibatidine binding sites. We calculated the variance of the product (K D IC 50 ) using a previously derived formula for the variance of the product of two independent random variables (Mood et al., 1974) . To avoid radioligand depletion, the maximum number of counts bound per well in the inhibitor experiments was kept to 300 ± 500 c.p.m. This level of binding yielded an adequate signal : noise ratio because the maximum number of counts bound per well was still 7 ± 15 times larger than the typical amount of nonspeci®c binding. The inhibitor experiments were replicated 2 ± 4 times.
Immunodepletion with mAb 270
Dr Kenneth Dorshkind (University of California, Los Angeles, CA, U.S.A.) provided the mAb 270 ascites used for the immunodepletion experiments. Further antibody puri®cation was unnecessary because the ascites was obtained from severe combined immunode®cient (SCID) mice. Comparisons between the amount of receptor bound to wells coated with 2 mg of mAb 299 and wells coated with 2 ml of mAb 270 ascites suggest that the mAb 270 ascites contained 1 ± 2 mg antibody ml 71 (assuming similar immunoprecipitation eciencies for both antibodies). To immunodeplete the b2-containing nicotinic receptors, the rat brain extracts were subjected to three serial overnight incubations with mAb 270 at 48C (25 ± 50 mg antibody (ml of rat brain extract added) 71 ) before immunoprecipitation onto the EIA/RIA strip plates. After each overnight incubation, 100 ml of extract was rotated with 50 ml of a 20% slurry of Protein G sepharose beads (Pharmacia, Piscataway, NJ, U.S.A.) for 3 h at 48C to collect the immune complexes. The sample was centrifuged and the supernatant was collected after incubation with the beads. After the third mAb 270 pre-incubation, we immunoprecipi-tated the remaining receptors onto EIA/RIA strip plates and measured +[ 3 H]-epibatidine binding. To control for nonspeci®c protein loss, aliquot parts of the rat brain extract were processed exactly as above but without mAb 270.
Serial Triton X-100 extraction
To determine whether a single detergent extraction removed all of the Triton X-100-soluble nicotinic receptors from the rat brain homogenates, we performed two extractions in series. In the ®rst extraction, rat brain tissue was solubilized with 2% Triton X-100 and centrifuged as described above. We then measured 30 nM +[
3 H]-epibatidine binding to the initial supernatant, re-solubilized the initial pellet in lysis buer, centrifuged the mixture, and measured +[ 3 H]-epibatidine binding to the supernatant from the re-solubilized pellet. The supernatant from the re-solubilized pellet contained 11% of the total +[ 3 H]-epibatidine bound to the combined extracts from the initial homogenate and re-solubilized pellet. Therefore, a single detergent extraction removed 89% of the Triton X-100-soluble receptors from the homogenates.
MAb 299 immunoprecipitation eciency
We used serial immunodepletions to measure the eciency of mAb 299 immunoprecipitation. The Triton X-100 extract from oocytes expressing a4b2 receptors was divided into seven groups of aliquot parts (four aliquot parts per group). Group 1 was incubated once overnight in mAb-299-coated EIA/RIA strip plate wells (2 mg antibody per well) and then the +[
3 H]-epibatidine bound to the wells, after a 40 min incubation in a saturating concentration of +[ 3 H]-epibatidine (30 nM), was measured. The six remaining groups were divided into experimentals (groups 2 ± 4 and controls (groups 5 ± 7). Groups 2 ± 4 were pre-incubated 1 ± 3 times in mAb-299-coated wells before a ®nal overnight incubation in mAb-299-coated wells. Groups 5 ± 7 were similarly pre-incubated 1 ± 3 times in blocked, uncoated wells before a ®nal overnight incubation in mAb-299-coated wells. Nonspeci®c receptor loss was estimated by dividing +[ (Houghtling et al., 1995) (Houghtling et al., 1995) and the B max (*50 fmol (mg protein) 71 ) for 7[ 3 H]-nicotine binding to non-detergent rat brain membrane extracts (Marks et al., 1986) . However, previous results show that Triton X-100 (1%) extraction enriches the density of [
Results
Kinetics of +[
3 H]-nicotine binding sites per mg of protein in rat brain extracts (Abood et al., 1980) . Therefore, rat brain nicotinic receptors represent a greater fraction of the Triton X-100-soluble rat brain proteins than of the total rat brain proteins. H]-epibatidine, followed by the addition of 1 mM cold (7)nicotine at time zero. The line is a ®t to:
where t is the time after the addition of 1 mM (7) ). The error bars are +s.e.mean but are obscured by the symbols in most cases (n=2 replicates). The line is a non-linear, least-squares ®t to a two-binding site model, 
Most mAb-299-precipitated rat brain receptors contain b2
The b4 subunit is present in the rat brain (Dineley-Miller & Patrick, 1992) and forms functional nicotinic receptors with a4 subunits in Xenopus oocytes (Duvoisin et al., 1989) . However, it is far less abundant than the b2 subunit (Zoli et al., 1995) . To determine what percentage of mAb-299-precipitated rat brain receptors contain b2, we measured the fraction of maximum +[ 3 H]-epibatidine, similar to the 40% occupancy rate predicted from the kinetic data ( Figure 1A,B Table 1 ). Figure 8A shows the structure of the novel antagonist NDNI. At a concentration of 30 pM +[
3 H]-epibatidine, we were primarily measuring antagonism of the high-anity +[
3 H]-epibatidine binding sites because the fractional occupancy of the low-anity sites was only 3 ± 5% at this +[ 
8B) inhibition of +[
3 H]-epibatidine binding (Table 1) . However, the DHbE K i s for the native and heterologously expressed receptors (50 ± 130 nM, (Whiting & Lindstrom, 1987; Flores et al., 1991) , our High-anity
Rat a4b2 Table 1 for the DHbE IC 50 s and K i s. The error bars are +s.e.mean (n=4 for rat brain; n=2 for a4b2 receptors expressed in oocytes and CV-1 cells with adenovirus). immunodepletion experiments further show that most a4-containing nicotinic receptors in the rat brain also contain b2. Moreover, a4b2 receptors expressed in native brain neurons, oocytes, and CV-1 cells with adenovirus all exhibit both highand low-anity +[
3 H]-epibatidine binding. Previous studies of chick brain nicotinic receptors immunoprecipitated with mAb 299 show that the pharmacological properties and macromolecular size of these receptors also resemble those of heterologously expressed chick a4b2 nicotinic receptors immunoprecipitated with the anti-b2 antibody mAb 290 (Whiting et al., 1991) .
Nicotinic receptors in rat forebrain homogenates display both high-(K D =15 pM) and low anity (K D =360 pM) +[
3 H]-epibatidine binding (Houghtling et al., 1995) . Our experiments show that a4 subunits are present in both types of binding sites. MAb 270 immunodepletion experiments further show that 89% of the mAb-299-precipitated binding sites contain b2. Since the high-anity sites account for only 74% of the total mAb-299-precipitated rat brain +[
3 H]-epibatidine binding sites, at least some low-anity rat brain receptors (558%) must contain both a4 and b2 subunits. In support of this hypothesis, we ®nd that a4b2 receptors expressed in Xenopus oocytes and CV-1 cells display both low-and high-anity +[ 3 H]-epibatidine binding.
Comparisons between the properties of native and recombinant ganglionic nicotinic receptors Lewis et al., 1997) suggest that the host cell can aect the biophysical properties of ganglionic nicotinic receptors. The relative sensitivity of rat nicotinic receptors in the rat superior cervical ganglion (SCG) to dierent nicotonic agonists (except DMPP) resembles that of rat a3b4 receptors expressed in Xenopus oocytes (Covernton et al., 1994) . However, the singlechannel conductance and burst duration of the native rat SCG receptors are signi®cantly dierent Sivilotti et al., 1997) . In contrast, mouse ®broblasts expressing rat a3b4 receptors contain one population of nicotinic channels with properties resembling those of the native SCG nicotinic receptor and another with properties resembling those of the rat a3b4 receptors expressed in Xenopus oocytes Sivilotti et al., 1997) . Thus, mammalian cell lines, but not Xenopus oocytes, appear to be capable of assembling a population of a3b4 channels with single-channel properties similar to the native ones.
The host cell type appears to aect the properties of brain nicotinic receptors less than those of ganglionic nicotinic receptors. The conductance (49 pS) of rat a4b2 channels expressed in oocytes closely matches that of human a4b2 channels (46 pS) expressed in HEK 293 cells (Buisson et al., 1996; Figl et al., 1998) . Moreover, the EC 50 and Hill coecient of rat and human a4b2 ACh concentration-response relations are nearly identical (Buisson et al., 1996; Figl et al., 1998) . Our results show that a4b2 nicotinic receptors immunoprecipitated from rat brain neurons, Xenopus oocytes, and CV-1 cells display similar pharmacological properties in regard to +[ Heterologous expression provides the only available means of studying the pharmacological and biophysical properties of identi®ed neuronal nicotinic receptor subtypes. The relevance of the results for heterologously expressed receptors depends on how closely the properties of those receptors match the properties of the native receptors. Our results show that rat a4b2 nicotinic receptors expressed in Xenopus oocytes and CV-1 cells display similar pharmacological behaviour in regard to at least three drugs, +[
3 H]-epibatidine, DHbE, and NDNI.
